tiprankstipranks
Longboard Pharmaceuticals (LBPH)
NASDAQ:LBPH
US Market
Holding LBPH?
Track your performance easily

Longboard Pharmaceuticals (LBPH) Income Statement

305 Followers

Longboard Pharmaceuticals Income Statement

Last quarter (Q3 2024), Longboard Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Longboard Pharmaceuticals's net income was $-24.54M. See Longboard Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
----$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 87.45M$ 56.76M$ 44.80M$ 27.84M$ 14.40M
Operating Income
$ -87.45M$ -56.76M$ -44.80M$ -27.84M$ -14.40M
Net Non Operating Interest Income Expense
$ 11.26M$ 2.40M$ 837.00K$ 64.00K$ 0.00
Other Income Expense
$ -335.00K$ -68.00K$ 16.00K$ 164.00K-
Pretax Income
$ -76.14M$ -54.42M$ -43.95M$ -27.99M$ -14.40M
Tax Provision
-----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -76.75M$ -54.42M$ -43.95M$ -27.99M$ -14.40M
Basic EPS
$ -2.24$ -2.39$ -2.56$ -1.93$ -0.85
Diluted EPS
$ -2.24$ -2.39$ -2.56$ -1.93$ -0.85
Basic Average Shares
$ 137.83M$ 22.73M$ 17.15M$ 14.41M$ 16.92M
Diluted Average Shares
$ 137.83M$ 22.73M$ 17.15M$ 14.41M$ 16.92M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 87.45M$ 56.76M$ 44.80M$ 27.84M$ 14.40M
Net Income From Continuing And Discontinued Operation
$ -76.34M$ -54.42M$ -43.95M$ -27.80M$ -14.40M
Normalized Income
$ -56.69M$ -42.55M--$ -14.40M
Interest Expense
-----
EBIT
$ -80.01M$ -56.76M$ -44.80M$ -27.99M$ -14.40M
EBITDA
$ -78.15M$ -56.75M$ -44.79M$ -27.83M$ -14.40M
Currency in USD

Longboard Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis